Alexion Data Presented at the 2025 AAN Annual Meeting Highlight Advancements in Improving Care for Rare Neurological Diseases
March 28, 2025
March 28, 2025
WILMINGTON, Delaware, March 28 -- AstraZeneca, a biopharmaceutical company, issued the following news release on March 27, 2025:
* * *
Alexion data presented at the 2025 AAN Annual Meeting highlight advancements in improving care for rare neurological diseases
Clinical and real-world evidence will reinforce the long-term safety profile and sustained efficacy of ULTOMIRIS and SOLIRIS(R) in NMOSD and gMG
Alexion, AstraZeneca Rare Disease, will pr . . .
* * *
Alexion data presented at the 2025 AAN Annual Meeting highlight advancements in improving care for rare neurological diseases
Clinical and real-world evidence will reinforce the long-term safety profile and sustained efficacy of ULTOMIRIS and SOLIRIS(R) in NMOSD and gMG
Alexion, AstraZeneca Rare Disease, will pr . . .